1 February 2024 false No description of principal activity Taxfiler 2024.6 10583771business:PrivateLimitedCompanyLtd2024-02-012025-01-31 105837712024-01-31 105837712024-02-012025-01-31 10583771business:AuditExempt-NoAccountantsReport2024-02-012025-01-31 10583771business:FilletedAccounts2024-02-012025-01-31 105837712025-01-31 10583771business:Director12024-02-012025-01-31 10583771business:RegisteredOffice2024-02-012025-01-31 105837712024-01-31 10583771core:WithinOneYear2025-01-31 10583771core:WithinOneYear2024-01-31 10583771core:ShareCapitalcore:PreviouslyStatedAmount2025-01-31 10583771core:ShareCapitalcore:PreviouslyStatedAmount2024-01-31 10583771core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-01-31 10583771core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-01-31 10583771core:PreviouslyStatedAmount2025-01-31 10583771core:PreviouslyStatedAmount2024-01-31 10583771business:SmallEntities2024-02-012025-01-31 10583771countries:EnglandWales2024-02-012025-01-31 10583771core:FurnitureFittings2024-02-012025-01-31 10583771core:FurnitureFittings2024-01-31 10583771core:FurnitureFittings2025-01-31 105837712023-02-012024-01-31 iso4217:GBP xbrli:pure
Company Registration No. 10583771 (England and Wales)
Asim Pharma Limited Unaudited accounts for the year ended 31 January 2025
Asim Pharma Limited Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Asim Pharma Limited Company Information for the year ended 31 January 2025
Director
Asim Malik
Company Number
10583771 (England and Wales)
Registered Office
6 Sandymoor Allerton Bradford West Yorkshire BD15 9LF England
Accountants
Taj Javed Ltd Chartered Certified Accountants 28 Haslingden Drive, Heaton Bradford West Yorkshire BD9 5HR
- 3 -
Asim Pharma Limited Statement of financial position as at 31 January 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Tangible assets
4
864 
1,054 
Current assets
Debtors
5
6,634 
6,491 
Cash at bank and in hand
9,671 
16,688 
16,305 
23,179 
Creditors: amounts falling due within one year
6
(15,781)
(17,811)
Net current assets
524 
5,368 
Net assets
1,388 
6,422 
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
1,288 
6,322 
Shareholders' funds
1,388 
6,422 
For the year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 30 October 2025 and were signed on its behalf by
Asim Malik Director Company Registration No. 10583771
- 4 -
Asim Pharma Limited Notes to the Accounts for the year ended 31 January 2025
1
Statutory information
Asim Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 10583771. The registered office is 6 Sandymoor, Allerton, Bradford, West Yorkshire, BD15 9LF, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
These financial statements for the year ended 31 January 2025 are the first financial statements that comply with FRS 102 Section 1A Small Entities. The date of transition is 1 February 2023. The transition to FRS 102 Section 1A Small Entities has resulted in a small number of changes in accounting policies to those used previously. The nature of these changes and their impact on opening equity and profit for the comparative period are explained in the notes below.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
18% Reducing balance basis
4
Tangible fixed assets
Fixtures & fittings 
£ 
Cost or valuation
At cost 
At 1 February 2024
2,340 
At 31 January 2025
2,340 
Depreciation
At 1 February 2024
1,286 
Charge for the year
190 
At 31 January 2025
1,476 
Net book value
At 31 January 2025
864 
At 31 January 2024
1,054 
- 5 -
Asim Pharma Limited Notes to the Accounts for the year ended 31 January 2025
5
Debtors
2025 
2024 
£ 
£ 
Amounts falling due within one year
Trade debtors
6,488 
6,345 
Accrued income and prepayments
146 
146 
6,634 
6,491 
6
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
Taxes and social security
13,723 
16,125 
Loans from directors
433 
891 
Accruals
1,625 
795 
15,781 
17,811 
7
Average number of employees
During the year the average number of employees was 2 (2024: 2).
- 6 -